Clinical Trial Update: Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas [Phase 2]

View source ↗

Summary

Phase 2 trial of sorafenib in children and young adults with recurrent or progressive low-grade astrocytomas, including patients with neurofibromatosis type 1–a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Glioma
• Neurofibromatosis Type
• Optic Pathway Glioma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: NYU Langone Health | Conditions: neurofibromatosis1 (NF1), Recurrent or Progressive Optic Pathway Gliomas (OPG) | Phase 2 | Status: TERMINATED | Results posted: 2016-02-22